Literature DB >> 10479056

HLA-G inhibits the allogeneic proliferative response.

B Riteau1, C Menier, I Khalil-Daher, C Sedlik, J Dausset, N Rouas-Freiss, E D Carosella.   

Abstract

HLA-G is a non-classical MHC class I molecule expressed at the feto/maternal interface where it plays a role in materno-fetal tolerance by inhibiting NK cells. Expression of killing inhibitory receptors capable of interacting with HLA-G on T lymphocytes led us to hypothesize that HLA-G molecules could also modulate T cell responses, analyzed here in the context of the allogeneic proliferative response. Using LCL-HLA-G transfectants as stimulators of T cells present among peripheral mononuclear cells and K562-HLA-G1 transfectants as inhibitors in a classical mixed lymphocyte reaction, we showed that HLA-G is able to inhibit T cell allo-proliferation. These findings provide new insight into the role of HLA-G in preventing allograft rejection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479056     DOI: 10.1016/s0165-0378(99)00034-0

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  38 in total

1.  Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism.

Authors:  N Lila; N Rouas-Freiss; J Dausset; A Carpentier; E D Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction.

Authors:  M Ueta; M-N Kweon; Y Sano; C Sotozono; J Yamada; N Koizumi; H Kiyono; S Kinoshita
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

3.  Different functional outcomes of intercellular membrane transfers to monocytes and T cells.

Authors:  Kiave-Yune HoWangYin; Estibaliz Alegre; Marina Daouya; Benoit Favier; Edgardo D Carosella; Joel LeMaoult
Journal:  Cell Mol Life Sci       Date:  2010-04       Impact factor: 9.261

4.  HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells?

Authors:  S Aractingi; N Briand; C Le Danff; M Viguier; H Bachelez; L Michel; L Dubertret; E D Carosella
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma.

Authors:  Simon Jasinski-Bergner; Christine Stoehr; Juergen Bukur; Chiara Massa; Juliane Braun; Stefan Hüttelmaier; Verena Spath; Roland Wartenberg; Wolfgang Legal; Helge Taubert; Sven Wach; Bernd Wullich; Arndt Hartmann; Barbara Seliger
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

Review 6.  CD8(+) Tregs in autoimmunity: learning "self"-control from experience.

Authors:  Sue Tsai; Xavier Clemente-Casares; Pere Santamaria
Journal:  Cell Mol Life Sci       Date:  2011-06-14       Impact factor: 9.261

7.  Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis.

Authors:  E Favoino; I E Favia; S Vettori; C Vicenti; M Prete; G Valentini; F Perosa
Journal:  Clin Exp Immunol       Date:  2015-05-10       Impact factor: 4.330

8.  Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors.

Authors:  Kiave-Yune HoWangYin; Maria Loustau; Juan Wu; Estibaliz Alegre; Marina Daouya; Julien Caumartin; Sylvie Sousa; Anatolij Horuzsko; Edgardo D Carosella; Joel LeMaoult
Journal:  Cell Mol Life Sci       Date:  2012-07-17       Impact factor: 9.261

Review 9.  Switch from protective to adverse inflammation during influenza: viral determinants and hemostasis are caught as culprits.

Authors:  Fatma Berri; Vuong Ba Lê; Martine Jandrot-Perrus; Bruno Lina; Béatrice Riteau
Journal:  Cell Mol Life Sci       Date:  2013-10-04       Impact factor: 9.261

10.  HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells.

Authors:  Joël LeMaoult; Irène Krawice-Radanne; Jean Dausset; Edgardo D Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.